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Abstract X-Linked hypophosphatemia (XLH) is the most
common form of hereditary rickets caused by loss-of
funct ion mutat ions in the PHEX gene. XLH is
characterized by hypophosphatemia secondary to renal
phosphate wasting, inappropriately low concentrations of
1,25 dihydroxyvitamin D and high circulating levels of
fibroblast growth factor 23 (FGF23). Short stature and
rachitic osseous lesions are characteristic phenotypic
findings of XLH although the severity of these manifestations
is highly variable among patients. The degree of growth
impairment is not dependent on the magnitude of
hypophosphatemia or the extent of legs´ bowing and height
is not normalized by chronic administration of phosphate
supplements and 1α hydroxyvitamin D derivatives.
Treatment with growth hormone accelerates longitudinal
growth rate but there is still controversy regarding the
potential risk of increasing bone deformities and body
disproportion. Treatments aimed at blocking FGF23 action
are promising, but information is lacking on the consequences
of counteracting FGF23 during the growing period. This
review summarizes current knowledge on phosphorus
metabolism in XLH, presents updated information on XLH
and growth, including the effects of FGF23 on epiphyseal
growth plate of the Hyp mouse, an animal model of the
disease, and discusses growth hormone and novel FGF23
related therapies.
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1 Phosphate homeostasis
Phosphate is an essential mineral, indispensable for a normal
bone and tooth development, it is critical for a wide array of
cellular processes and it is an integral component of the
nucleic acids. Normal values of serum phosphate in adults
vary from 2.4 to 4 mg/dL whereas children have higher levels,
i.e. between 4.8–7.4 mg/dL in the first 3 months of life and
between 4.5–5.8 mg/dL at 1–2 years [1]. In mammals includ-
ing humans, circulating concentration of inorganic phosphate
(Pi) is determined by renal and intestinal (predominantly in the
jejunum) uptakes and by its distribution between bone and
soft tissues [2]. To maintain a neutral balance, the amount of
absorbed phosphate has to be equal to the amount excreted in
the urine. Approximately, 75–85% of the phosphorus filtrated
by the glomeruli is reabsorbed in the proximal tubule. This
reabsorption of filtrated Pi is carried out by sodium-coupled
phosphate (NaPi) co-transporters localized at the apical mem-
brane of tubular cells [3]. In the brush border membrane three
cotransporters have been identified so far: NaPi-IIa (gen
SLC34A1), NaPi-IIc (gen SLC34A3) and, more recently, Pit-
2 (gen SLC20A2) [3–5]. In the intestine, NaPi-IIb
cotransporter mediates the transcellular phosphate transport.
The serum phosphate concentration is regulated by parathy-
roid hormone (PTH) and 1,25 dihydroxyvitamin D
[1,25(OH)2D]. PTH decreases the proximal tubular reabsorp-
tion of phosphate by reducing NaPi-IIa and NaPi-IIc activities.
This reduction is achieved by internalization of NaPi proteins
from the lumen side of the proximal tubular epithelial cells [6].
PTH also mobilizes phosphate from the skeletal into the blood-
stream, possibly by enhancing osteoclastic bone resorption. In
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addition, PTH increases the production of 1,25(OH)2D by in-
ducing the renal expression of 1-α-hydroxylase (CYP27B1)
and stimulates intestinal phosphate absorption [7]. CYP27B1
enzyme, located in the proximal tubule of the kidney and a
variety of other tissues, including bone osteoblasts [8], cata-
lyzes the hydroxylation of 25 hydroxyvitamin D to
1,25(OH)2D, the bioactive form of vitamin D.
In addition to PTH and vitamin D, other hormones can
affect renal phosphate handling. Growth hormone, insulin,
and thyroid hormone all increase phosphate tubular reabsorp-
tion, whereas calcitonin, glucocorticoids, and atrial natriuretic
factor decrease it.
The major recent breakthrough in understanding the active
regulation of phosphate homeostasis was accomplished by the
identification of fibroblast growth factor 23 (FGF23). FGF23
is an hormone mainly synthesized by osteocytes, but it has
also been identified in the endothelial cells of the venous si-
nusoids of the bone marrow and in the thymus of Hyp mouse
[9]. Its synthesis and secretion are positively regulated by
vitamin D and serum phosphorus [10, 11].When phosphorus
levels are too high, FGF23 inhibits the renal tubular reabsorp-
tion. FGF23 suppresses CYP27B1 transcription in the kidney
activity and stimulates catabolism of 1,25(OH)2D through 24-
hydroxylase enzyme (CYP24) (Fig. 1). Although elevated
FGF23 levels are involved in the pathogenesis of some forms
of hereditary and acquired hypophosphatemic rickets [12], its
physiological role in the regulation of phosphate metabolism
is still to be defined.
The protein klotho (KL) has been found to be critical for
FGF23 signaling [13]. Klotho is an essential cofactor for
FGF23. Membrane-bound-klotho interacts with FGF receptors
(FGFR) in proximal tubular cells to form a high affinity recep-
tor for FGF23. FGFR4 or the IIIc isoforms of FGFR1 and
FGFR3 [14–16] form an heteromeric complex, FGF23-KL-
FGFR, which activates the mitogen activated protein kinase
(MAPK) cascade and induces the phosphorylation of ERK1/
2 (p-ERK1/2) [17, 18]. In the end, activation of this pathway
results in the reduction of NaPi-IIa and NaPi-IIc protein ex-
pression in the kidney (Fig. 2) and in the inhibition of
1,25(OH)2D synthesis [19]. Reduction of the 1,25(OH)2D
levels may lead to a decrease in intestinal type NaPi-IIb trans-
porter and also to a reduction of intestinal Pi absorption. In fact,
KL-knockout mice exhibit overexpression of NaPi-IIa and
NaPi-IIc proteins with concomitant hyperphosphatemia [20].
Interestingly, KL exists also as a circulating form that likely
has a distinct mode of action. Recent studies have shown that
secreted KL can act independently from FGF23 and directly
inactivate the expression of NaPi-IIa inducing phosphaturia
[21, 22]. It has been suggested that secreted KL can influence
Na+-K+-ATPase activity, which results in an increased Na+ ion
gradient and enhances trans-epithelial calcium transport in the
choroid plexus and the kidneys [23]. Indeed, secreted KL has
been shown to increase the tubular cell surface expression of
TRPV5 [24, 25], a channel involved in calcium reabsorption,
probably through FGFR1 and ERK 1/2 WNK4 pathway.
2 X-linked hypophosphatemia
X-Linked hypophosphatemia (XLH) (OMIM 307800) is the
most prevalent form of hereditary rickets and the most com-
mon inherited defect of renal tubular phosphate transport in
humans [26, 27]. Its frequency has been estimated to be 1 in
20,000. XLH is characterized by hypophosphatemia second-
ary to renal phosphate wasting, inappropriately low concen-
trations of 1,25(OH)2D and high levels of FGF23. Although
there is a large phenotypic variability, XLH patients exhibit
some degree of disproportional dwarfism with predominant
shortening of lower limbs, low mineral density and rickets
or osteomalacia [28, 29].
2.1 Genetic basis
XLH is caused by loss of function of the PHEX gene and its
transmission follows a X-dominant heritance [30–32]. Awide
array of mutations has been described [33], and among them a
significant number of sporadic cases resulting from de novo
PHEX mutations [34, 35]. The PHEX gene has 22 exons and
encodes a 749-amino acid protein that putatively consists of
an intracellular, transmembrane, and extracellular domain.
The Hyp-mouse, discovered in 1976 by Eva M. Eicher, is
the best completely characterized animal model of XLH [29,
30]. Hyp gene is homologous with the X-linked human gene,
which encodes a protein that belongs to the neutral endopep-
tidase family of zinc metalloproteinase [34]. Studies in the
Hyp mouse have shown that Phex is expressed chiefly in
osteoblast and osteoclast of bone and teeth but also in lung,
brain, ovary, testicle and muscle [31, 36].
2.2 Biochemical and molecular findings
Character is t ic biochemical f indings of XLH are
hypophosphatemia secondary to decreased tubular reabsorp-
tion of phosphate, insufficiently high concentrations of serum
1,25(OH)2D, elevated circulating levels of FGF23 and normal
serum calcium and PTH [37]. Serum alkaline phosphatase, a
marker of bone formation, is elevated in children who develop
rickets, and usually returns to normal in adulthood.
Studies carried out in parathyroidectomized Hyp mice in-
dicated that the exacerbated phosphaturia is not caused by
PTH [38] but more likely results from the decreased expres-
sion of the Pi transporters [39]. The identification of FGF23
has disclosed a major role of this hormone in the pathogenesis
of the disease. Elevated circulating levels of FGF23 have been
noted in Hyp mice [40] as well as in XLH patients [41].
Probably FGF23 increases renal phosphate excretion by
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reducing expression and activity of NaPi cotransporters as
well as by inhibiting the CYP27B1 enzyme [42] (Fig. 1).
As PHEX is the only gene having pathogenic variants
known to cause XLH, Liu et al. (2007) examined the mecha-
nism whereby FGF23 is regulated by Phex in transplanting
Hyp bones in wild type mice and vice-versa [40]. They found
that wild type bone explanted into Hyp mice developed oste-
omalacia and failed to normalize systemic FGF23 levels, sug-
gesting that the defective bone mineralization was caused by
circulating factors. On the other hand, FGF23was increased in
Hyp osteocytes before and after explantation into wild type
mice, but it was not modified in wild type mouse osteocytes
after explantation into Hyp mice, suggesting that FGF23 over-
expression resulted from an intrinsic bone Phex defect.
Unexpectedly, they also observed a paradoxical suppression
of FGF23 in juvenile Hyp bone explanted into adult Hyp
mice, indicating the presence of an age-dependent systemic
inhibitor of FGF23 that can be the real PHEX substrate. This
finding could explain why the disease appears to lessen in
severity with age [43, 44]. In addition, FGF23 levels are high-
ly variable in XLH patients [45], supporting the presence of
others factors that regulate FGF23. It remains unclear how
loss of function of PHEX results in elevated FGF23 levels.
2.3 XLH and growth
Short stature is a phenotypic hallmark of XLH. Adults with
XLH have a significantly reduced final height up to 20 cm,
mean standard deviation score (SDS) of −1.9 [44], but there is
a great variability among individuals. XLH patients are not
abnormally small at birth [46]; XLH girls and boys seem to
have normal growth spurt and adult men show a more severe
Fig. 1 Phosphorus metabolism in XLH. Inactivation of PHEX gene
results in increased circulating levels of FGF23. FGF23 directly
suppresses renal sodium-phosphate cotransporters (NaPi-IIa and NaPi-
IIc) and increases the urinary excretion of phosphate. Likewise, FGF23
suppresses the expression of 1-α hydroxylase (CYP27B1) and stimulates
the production of 24-hydroxylase (CYP24), so reducing 1,25(OH)2D
levels and hence the phosphate intestinal absorption mediated by
sodium-phosphate cotransporter NaPi-IIb. Prolonged phosphate restric-
tion it should increase not only 1,25(OH)2D level but also PTH, never-
theless XLH is associated with normal or slightly elevated serum para-
thyroid hormone. Therefore PHEX inactivation induces hyperphospaturia
and Hypophosphatemia and in the end XLH patients develop bone com-
plications and growth retardation
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XLH phenotype than women [46–49]. Otherwise, serum
phosphate concentrations and stature SDS have been shown
to keep a poor positive correlation in children with XLH.
Adults who began treatment with phosphate and
1,25(OH)2D earlier, manage to grow taller despite having a
similar degree of hypophosphatemia [50, 51]. In this regard,
Jehan et al. (2008) described changes in growth that are asso-
ciated with different vitamin D receptor promoter haplotypes,
providing a possible explanation for some of the clinical var-
iability observed in XLH [52]. On the other hand, defects in
growth hormone (GH) secretion have been reported in only a
few patients [47], and associated metabolic, inflammatory or
nutritional disorders have not been described in XLH individ-
uals. Thus, the adverse effect of XLH on growth seems to be
not dependent on GH disordered metabolism or nutritional
deficiencies.
A relevant point is that dwarfism of XLH patients is dis-
proportional, longitudinal shortening and the degree of the
deformity being more severe in lower extremities than in the
rest of the body [44, 50, 53] Bowing and/or twisting tend to
appear once a child begins to bear weight on his or her legs. In
fact, the diagnosis is frequently made in the first two years of
life, when lower-extremity bowing becomes evident.
Corrective surgical osteotomy is often required when correc-
tion of the torsion is not reversed by medical therapy.
Nevertheless, it is not clear that growth retardation can be only
explained by the bone bowing itself.
Bone mineral density is also decreased in children and
adolescents [54], often persists low into adulthood, and not
always improves with standards therapies [43, 54, 55]. This
bone weakness may affect the child’s daily life and increases
the possibility of developing arthritis over the years. Qiu et al.
Fig. 2 Model of FGF23-αKlotho signaling in renal distal tubular cells.
This figure shows the possible mode of action of FGF23/klotho in pro-
ducing hypophosphatemia and hyperphospaturia in XLH renal proximal
tubular cell. FGF23 binds to the basolateral FGFR-Klotho complex in
proximal tubular cells and activates ERK1/2 by phosphorylation. pERK1/
2 acts on the nucleus and induced a downregulation of NaPi-IIa/c
cotransporters expression. In a XLH cell, the pathogenic high levels of
FGF23 lead to ERK1/2 over-activation and to a dramatic reduction of
NaPi II a/c expression. Low presence of NaPi cotransporters in the apical
border membrane reduces the intracellular transport of phosphate in prox-
imal tubular cells, increment the phosphate excretion through the urine
and leads to the hyperphospaturia and hypophosphatemia
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(2004) showed in Hyp mice that there were not gender differ-
ences in bone mineral accrued between males and females
Hyp mice, but there were differences in vertebra length, indi-
cating that long bones’ rickets and osteomalacia follow differ-
ent mechanism and are not equally affected by gen dose [56].
Epiphyseal growth plate is responsible for the longitudinal
endochondral ossification and determines the final length of
bones. Defects in the development of this organ or fractures
can lead to growth complications. Physiologically, the rate and
extent of growth are determined by the combination of chon-
drocyte proliferation, matrix production, and enlargement of
hypertrophic chondrocytes [57]. The finding that PHEX is
strongly expressed not only by osteoblasts, but also by
chondrocytes, and its expression is influenced by transcription
factor of chondrogenesis [58], suggests that the loss of PHEX
function might directly contribute to the pathogenesis of
growth retardation and cartilage abnormalities. The anatomic
characteristics of the growth plate make its study extremely
difficult in the clinical setting and justify the use of animal
models for a better understanding of the mechanisms interfer-
ing with normal growth in XLH patients. Hyp mice have
profound abnormalities in the growth plate although a detailed
analysis of the structure and dynamics of growth plate carti-
lage in this animal model of XLH remains to be performed. It
is known that epiphyseal growth plates are proximally–distal-
ly thicker than normal growth plates [59]. These findings sug-
gest that the primary skeletal defect in Hyp mice is not caused
by abnormal osteoblast differentiation but rather by an impair-
ment in mineralization by osteoblasts [60]. Recent findings
indicate that FGF21, a member of the FGF family that like
FGF23 functions as an endocrine factor, directly inhibits
chondrocyte proliferation and differentiation at the growth
plate; so that FGF23 might be playing a causal role in the
abnormal process of growth plate [61].
Studies in humans and mice raised the question as to
whether normalization of serum calcium, phosphate, or both
was required to normalize the growth plate phenotype and
therefore the final length. The calcium sensing receptor KO
mouse CasR (a murine model of familial hypercalcemia) has
high serum calcium, low circulating phosphate levels and de-
velops a rachitic growth plate in the presence of hyperpara-
thyroidism. However, when this mouse is mated with a
Gcm2null-mouse (mice lacking parathyroid glands) [62],
resulting mice develop hypocalcemia combined with
normophosphatemia and mild hypoparathyroidism.
Therefore, it can be concluded that the correction of PTH
and Pi levels are crucial for a normal cartilage development
[63]. Sabbagh et al. (2005) found decreased apoptosis rate,
assessed by TUNEL technique and cleaved caspase 3 activity
in hypertrophic chondrocytes of Hyp mouse versus wild type
mouse growth plate [64], demonstrating that normal phospho-
rus levels are also required for hypertrophic chondrocyte cell
death. Likewise Shiguang Liu et al. (2007) explanted Hyp
bones in wild type mice showing that Hyp bones near normal-
ized the growth plate width [40] when they are in a normal
phosphorus environment.
Thus, all these studies point to phosphate as well as FGF23
as important regulators of growth plate maturation and bone
formation [65].
2.4 XLH treatment
In humans, growth deceleration and rickets in XLH begin to
occur during the first 2 years of age when the growth velocity
is physiologically maximum. Therefore, the early initiation of
treatment is essential, before overt manifestation of rickets and
growth retardation develop [46]. Pharmacologic treatment in
XLH patients consists of oral phosphate supplementation and
1-alpha hydroxyvitamin D derivatives’ administration.
Although this therapy usually leads to an improvement of
biochemical parameters and amelioration of rickets [66], the
effects on longitudinal growth are often disappointing and
some patients remain unresponsive [55]. On the other hand,
the risk of hypercalcemia, hypercalciuria, hyperparathyroid-
ism and nephrocalcinosis as well as the gastrointestinal toler-
ance to phosphate limit the progressive increase in the doses of
1-α hydroxyvitamin D derivatives and phosphate [67, 68].
Recent data from a multi-center Austrian - German study on
76 children with XLH showed progressive deterioration of
height, expressed as SDS, despite continued treatment with
phosphate and calcitriol [50]. Another study in 23 adult pa-
tients showed a decreased joint mobility despite the treatment
with vitamin D and phosphorus [43]. It is also of note that,
despite inappropriate baseline elevations in FGF23 concentra-
tions in XLH patients, standard treatment with calcitriol and
phosphate further increases levels of this hormone [69, 70].
2.4.1 Growth hormone treatment
Pediatric patients with XLH have been treated with recombi-
nant human GH (rhGH) [71]. Maintained doses of rhGH have
shown an improvement in growth velocity and phosphate
concentrations [46, 48, 50, 72], however, there are not clear
evidences about the effectiveness of the treatment [50]. A 3-
year-study carried out by Haffner et al. (2004) in rhGH treated
children showed potential hormone benefit over the final
height but failure to normalize the body disproportion [73].
In poorly growing XLH patients, rhGH therapy added to the
conventional treatment with vitamin D metabolites and phos-
phate improved final height, phosphate retention and radial
bone mineral density but did not modify the disharmonic de-
velopment [48]. Animal studies have mostly focused on ex-
amine the short-term effect of GH treatment on vitamin D
metabolism and renal phosphate transport [74] rather than
the long-term effect on growth.
Rev Endocr Metab Disord
Author's personal copy
2.4.2 New FGF23 related therapies
Tumor induced osteomalacia (TIO) has been proposed to have
an overlapping pathophysiology with XLH, since PHEX is also
present in the tumors, raising the possibility that TIO and XLH
share components of a common pathogenic mechanism. In fact,
in some TIO patients high levels of FGF23 have been identified
to cause osteomalacia as well as hypophosphatemia [75, 76]. It
would be of interest to know whether the inhibition of FGF23
activity is useful or not for patients with hypophosphatemic
rickets/osteomalacia caused by excessive activity of FGF23
[77]. In this respect there are not many studies in Hyp mouse
[78–84] and only two in humans [85, 86].
Two studies in wild type and Hyp mice have shown that the
inhibition of the FGFR effectively blocks FGF23 function and
it partially corrects the hypophosphatemia of the mutant mouse
[77, 78]. Wöle et al. (2013) have assessed the potential use of
FGFR inhibitors during long term periods in Hyp mice. They
used NVP-BGJ398, a novel FGFR inhibitor, currently being
used in phase I clinical trials as cancer therapy. Drug was orally
administered during 5 weeks in adult Hyp mice [80] leading to
enhanced bone growth, increased mineralization, and reorgani-
zation of the disturbed growth plate structure.
As for FGF23 inhibition, a single dose of anti-murine
FGF23 antibody given to Hyp mice increased serum calcitriol
whereas repeated injections ameliorated rickets and bone min-
eralization [81, 82]. In the only prolonged study in humans, 4-
month administration of KRN23 (a recombinant human IgG1
monoclonal antibody that binds to FGF23 and blocks its bio-
logical activity) resulted in significantly increased serum
phosphate, renal phosphate reabsorption, and circulating
1,25(OH)2D concentrations in 28 XLH adult patients [85].
It has also been shown that MAPK signaling mediated by
ERK1/2 is necessary for the suppressive effects of FGF23 on
renal Pi reabsorption and calcitriol production [17, 80, 83]
(Fig. 2). In Hyp mice, Zang et al. (2012) showed that the
inhibition of this pathway, improved serum phosphate and
1,25(OH)2D concentrations as well as osseous lesions of rick-
ets or osteomalacia regardless the persistently elevated sys-
temic levels of FGF23 [84]. They hypothesized that other
molecules apart from FGF23 must be contributing to the path-
ogenesis of the disease. In this regard, crossing mice homozy-
gous for the null Cyp24 allele, the mitochondrial enzyme re-
sponsible for inactivating 1,25(OH)2D, with Hyp mice [79]
led to offspring having high circulating levels of FGF23 but
lacking CYP24 enzymatic activity. In these animals, serum
concentrations of phosphate and 1,25(OH)2D did not improve
but the rachitic/osteomalacic bone abnormalities and ab-
normal growth plate were ameliorated independently of
the levels of FGF23. Thus, bone and growth plate dis-
turbances in XLH may be dependent on the autocrine/
paracrine effects of vitamin D rather than on circulating
phosphorus and FGF23 levels.
3 Areas of research and development
XLH, the most prevalent inherited rickets, is caused by loss of
function of the PHEX gene and biochemically characterized
by low serum phosphate concentration, reduced tubular reab-
sorption of phosphate and high circulating levels of FGF23.
The mechanisms whereby inactivation of PHEX causes these
alterations remain unclear.
XLH patients show a wide phenotypic variability but short
stature and body disproportion with some degree of legs’
bowing are key clinical manifestations. The reason for growth
impairment in XLH is not completely clear because the reduc-
tion in height does not entirely depend on the severity of lower
extremities’ deformity. It is of note that few data are available
on the abnormalities of the growth plate in XLH, even in the
Hyp mouse which is a good animal model of the disease. The
impact of XLH on the normal structure and dynamics of
growth plate chondrocytes and the relationship of these alter-
ations on longitudinal growth rate are areas of further research.
Height is not normalized by sustained treatment with phos-
phate and calcitriol and although GH therapy has been shown
to accelerate growth velocity there are some concerns on its
potential to exaggerate body disproportion. Studies on the
administration of GH in Hyp mice have mostly focused on
the ability of GH to improve phosphate and vitamin D metab-
olism but there is a lack of information on its effects on growth
plate. In addition, treatments aimed at blocking FGF23 action
are promising but, again, information is lacking on the conse-
quences of counteracting FGF23 on the growth plate.
In conclusion, despite rickets and bone bowing being the
most noticeable symptoms of the XLH disorder, most of the
treatments are focused on phosphorus and vitamin D metab-
olism. Consequently, it is essential to understand the mecha-
nism underlying the growing impairment and how conven-
tional and new treatments affect in this regard.
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